Overview

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

Status:
Not yet recruiting

Trial end date:
2025-05-20

Target enrollment:

Participant gender:

Summary

A clinical trial to compare the effectiveness of savolitinib plus durvalumab versus sunitinib in MET-driven (hepatocyte growth factor receptor), unresectable and locally advanced or metastatic PRCC (Papillary Renal Cell Carcinoma)

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Durvalumab
Sunitinib